Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1860657
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: ALLR
TL;DR
ALLR filed an 8-K, mostly financial docs. No major news.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on October 23, 2024, reporting on events as of October 22, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This 8-K filing indicates Allarity Therapeutics is providing updated financial statements and exhibits to the SEC, which is a standard regulatory requirement.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- 0001860657 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification
- 03 Life Sciences (company) — Organization Name
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-41160 (company) — SEC File Number
- 24 School Street, 2nd Floor, Boston, MA 02108 (company) — Business Address
- 401-426-4664 (company) — Business Phone
FAQ
What is the primary purpose of this 8-K filing by Allarity Therapeutics?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of October 22, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on October 23, 2024.
What is Allarity Therapeutics, Inc.'s Central Index Key (CIK)?
Allarity Therapeutics, Inc.'s Central Index Key is 0001860657.
What is the business address and phone number listed for Allarity Therapeutics?
The business address is 24 School Street, 2nd Floor, Boston, MA 02108, and the phone number is (401) 426-4664.
Does this filing indicate any specific new material events or agreements?
Based on the provided text, this filing primarily concerns financial statements and exhibits, and does not detail specific new material events.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-10-23 08:01:13
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
Filing Documents
- allr20241022_8k.htm (8-K) — 29KB
- ex_735811.htm (EX-99.1) — 13KB
- atlogosmall.jpg (GRAPHIC) — 6KB
- 0001437749-24-031806.txt ( ) — 191KB
- allr-20241022.xsd (EX-101.SCH) — 3KB
- allr-20241022_def.xml (EX-101.DEF) — 12KB
- allr-20241022_lab.xml (EX-101.LAB) — 16KB
- allr-20241022_pre.xml (EX-101.PRE) — 12KB
- allr20241022_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 22, 2024, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing that the European Patent Office (EPO) has issued a formal notice of its intention to grant a patent for the Company's Drug Response Predictor (DRP) companion diagnostic specific to stenoparib, the Company's dual-targeted PARP-Tankyrase inhibitor.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated October 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: October 23, 2024 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer